Join to View Full Profile
4100 John R StDetroit, MI 48201
Phone+1 800-527-6266
Fax+1 313-831-4065
Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 2008 - 2011- Ascension Providence/MSUCHMResidency, Internal Medicine, 2005 - 2008
- Henry Ford Providence HospitalInternship, Transitional Year, 2004 - 2005
University of Michigan Medical SchoolClass of 1998
Certifications & Licensure
MI State Medical License 2004 - 2026
American Board of Internal Medicine Hematology
Clinical Trials
- Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Start of enrollment: 2021 Nov 11
- A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Start of enrollment: 2020 Aug 07
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2022 Dec 12
- Join now to see all
Publications & Presentations
PubMed
- Comprehensive Age-Stratified Impact ofMutation in Acute Myeloid Leukemia: A Real-World Experience.Vikram Dhillon, Abdul Moiz Khan, Jeff Justin M Aguilar, Sushmitha Nanja Reddy, Mai M Aly
Cancers. 2025-03-18 - Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort op...Jorge E Cortes, Gail J Roboz, Maria R Baer, Brian A Jonas, Gary J Schiller
Journal of Hematology & Oncology. 2025-01-16 - ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.Jenna L Carter, Yongwei Su, Eman T Al-Antary, Jianlei Zhao, Xinan Qiao
Journal of Experimental & Clinical Cancer Research. 2025-01-09
Abstracts/Posters
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What Is Leukemia? Symptoms, Causes and TreatmentJune 23rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
